These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8004629)

  • 1. High dose chemotherapy with autologous stem cell support for the treatment of metastatic breast cancer.
    Ayash LJ
    Cancer; 1994 Jul; 74(1 Suppl):532-5. PubMed ID: 8004629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
    Ayash LJ; Elias A; Wheeler C; Tepler I; Schwartz G; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(4):507-11. PubMed ID: 7916250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
    Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
    Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D
    Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer.
    Farquhar C; Basser R; Hetrick S; Lethaby A; Marjoribanks J
    Cochrane Database Syst Rev; 2003; (1):CD003142. PubMed ID: 12535458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer.
    Farquhar C; Marjoribanks J; Basser R; Hetrick S; Lethaby A
    Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD003142. PubMed ID: 16034887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma.
    Ayash LJ; Elias A; Ibrahim J; Schwartz G; Wheeler C; Reich E; Lynch C; Warren D; Shapiro C; Richardson P; Hurd D; Schnipper L; Frei E; Antman K
    J Clin Oncol; 1998 Mar; 16(3):1000-7. PubMed ID: 9508183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
    Sola Rocabert C; Mesía R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G
    Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
    Stadtmauer EA; O'Neill A; Goldstein LJ; Crilley PA; Mangan KF; Ingle JN; Brodsky I; Martino S; Lazarus HM; Erban JK; Sickles C; Glick JH
    N Engl J Med; 2000 Apr; 342(15):1069-76. PubMed ID: 10760307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer.
    Marks LB; Rosner GL; Prosnitz LR; Ross M; Vredenburgh JJ; Peters WP
    Cancer; 1994 Dec; 74(11):2964-71. PubMed ID: 7954260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
    Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
    J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
    Bearman SI; Overmoyer BA; Bolwell BJ; Taylor CW; Shpall EJ; Cagnoni PJ; Mechling BE; Ronk B; Barón AE; Purdy MH; Ross M; Jones RB
    Bone Marrow Transplant; 1997 Dec; 20(11):931-7. PubMed ID: 9422471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer.
    Ayash LJ; Wheeler C; Fairclough D; Schwartz G; Reich E; Warren D; Schnipper L; Antman K; Frei E; Elias A
    J Clin Oncol; 1995 Aug; 13(8):2043-9. PubMed ID: 7636547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
    Ayash LJ; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher BA; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
    J Clin Oncol; 1996 Nov; 14(11):2984-92. PubMed ID: 8918496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results.
    Hillner BE; Smith TJ; Desch CE
    JAMA; 1992 Apr; 267(15):2055-61. PubMed ID: 1552641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Sniecinski I
    Cancer; 1994 Jan; 73(1):125-34. PubMed ID: 7903906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer.
    Eddy DM
    J Clin Oncol; 1992 Apr; 10(4):657-70. PubMed ID: 1285731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous bone marrow transplantation for metastatic breast cancer.
    Saez RA; Selby GB; Slease RB; Epstein RB; Mandanas RA; Confer DL
    J Okla State Med Assoc; 1994 Sep; 87(9):405-10. PubMed ID: 7996314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.